Breaking News
Black Friday SALE: Up to 54% off InvestingPro! Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Compugen (CGEN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1,453 +40    +2.83%
25/11 - Closed. Currency in ILS ( Disclaimer )
Type:  Equity
Market:  Israel
ISIN:  IL0010852080 
S/N:  1085208
  • Volume: 86,767
  • Bid/Ask: 1,455 / 1,457
  • Day's Range: 1,430 - 1,459
Compugen 1,453 +40 +2.83%
IndustryLife Sciences Tools & Services
SectorHealthcare
Employees

68

Equity Type

ORD

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Contact Information

Phone 972 3 765 8585
Fax 972 3 765 8555

Top Executives

Name Age Since Title
Jean-Pierre Bizzari 67 2018 Independent Director
Eran Perry 50 2019 Independent Director
Antoni Ribas 54 2013 Member of Scientific Advisory Board
Howard R. Soule - 2013 Member of Scientific Advisory Board
Iain B. McInnes - 2013 Member of Scientific Advisory Board
Nils Lonberg 65 2020 Member of Scientific Advisory Board
Paul J. Sekhri 63 2017 Independent Chairman of the Board
Drew Mark Pardoll - 2014 Chairman of Scientific Advisory Board
Anat Cohen-Dayag 54 2006 CEO, President & Director
Kinneret Livnat-Savitzky 54 2000 Independent Director
Gilead Halevy 55 2018 Independent Director
Miriam Merad - 2017 Member of Scientific Advisory Board
Sanford S. Zweifach 65 2018 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CGEN Comments

Write your thoughts about Compugen
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Marcel Demers
Marcel Demers Nov 16, 2021 10:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Currently being valued ~315M counting cash on hand and no debt.
Mister Bert
Mister Bert Feb 19, 2021 1:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Well my prediction came true and my $12 order filled today. Immediately it jumped up and I am up over 3% same day. Hoping this follows through with my prediction that it will be going up from here to $15!
Mister Bert
Mister Bert Feb 19, 2021 1:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
So wrong I was. Entire market crashed lol
Mister Bert
Mister Bert Feb 08, 2021 1:13PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Falling wedge pattern. If it doesn't break out now, will fall back down to $12. Buy it then! Good chance it will sky rocket to $15 or more.
Mister Bert
Mister Bert Jan 22, 2021 5:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
any news?
Robert Schrum
Robert Schrum May 27, 2020 10:54PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
with a buy stop above $16, short around $13.50-$14. GL
Peter Ballsnbush
BoyYeetzWorld May 27, 2020 10:54PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Really hope you didn't short
משה משה
משה משה Apr 29, 2020 8:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Amazing news to come. The stock is about to fly very high.
chad gray
chad gray Feb 07, 2020 6:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Looking strong on trend as etf’s are buying up this stock in large amounts
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email